The role of topical therapies along the psoriasis patient journey: An overview from the Symposium 'Tailoring topical psoriasis treatments to patients' needs and expectations' of the 30
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
14
06
2022
accepted:
12
09
2022
entrez:
22
12
2022
pubmed:
23
12
2022
medline:
24
12
2022
Statut:
ppublish
Résumé
This article summarizes a presentation titled 'The role of topical therapies along the psoriasis patient journey' held at the Satellite Symposium of the 30
Substances chimiques
Dermatologic Agents
0
Betamethasone
9842X06Q6M
Drug Combinations
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3-8Subventions
Organisme : Almirall, Barcelona, Spain
Informations de copyright
© 2022 European Academy of Dermatology and Venereology.
Références
Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70:871-81.e1-30.
Lebwohl M, Langley RG, Paul C, Puig L, Reich K, van de Kerkhof P, et al. Evolution of patient perceptions of psoriatic disease: results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. Dermatol Ther (Heidelb). 2022;12:61-78.
World Health Organization. Global report on psoriasis. 2016 [last accessed 2022 Apr 12]. Available from: https://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189_eng.pdf.psoriasis?sequence=1
Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PCM, Chimenti S, Lotti T, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;155:729-36.
Maul J-T, Anzengruber F, Conrad C, Cozzio A, Häusermann P, Jalili A, et al. Topical treatment of psoriasis vulgaris: the Swiss treatment pathway. Dermatology. 2021;237:166-78.
van de Kerkhof PCM, Reich K, Kavanaugh A, Bachelez H, Barker J, Girolomoni G, et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Dermatol Venereol. 2015;29:2002-10.
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CEM, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1-10.
Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, et al. German S3-guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - part 2: treatment monitoring and specific clinical or comorbid situations. J Dtsch Dermatol Ges. 2021;19:1092-115.
Lebwohl M, Thaçi D, Warren RB. Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis. J Eur Acad Dermatol Venereol. 2021;35(Suppl 1):35-41.
Körber A, Wilsmann-Theis D, Augustin M, Kiedrowski R, Mrowietz U, Rosenbach T, et al. Topische Therapie bei Psoriasis vulgaris - ein Behandlungspfad. J Dtsch Dermatol Ges. 2019;17(Suppl 4):3-14.
Aschoff R, Martorell A, Anger T, Chayer D, Bewley A. Real-world experience using topical therapy-calcipotriol and betamethasone dipropionate foam in adults with beyond-mild psoriasis. Dermatol Ther (Heidelb). 2021;11:555-69.
Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84:432-70.
Thaçi D, Ortonne J-P, Chimenti S, Ghislain PD, Arenberger P, Kragballe K, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol. 2010;163:402-11.
van de Kerkhof PCM, Wasel N, Kragballe K, Cambazard F, Murray S. A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity. Dermatology. 2005;210:294-9.
Segaert S, Calzavara-Pinton P, de la Cueva P, Jalili A, Lons Danic D, Pink AE, et al. Long-term topical management of psoriasis: the road ahead. J Dermatolog Treat. 2022;33:111-20.
Puig L, Carrascosa JM, Belinchón I, Fernández-Redondo V, Carretero G, Ruiz-Carrascosa JC, et al. Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013;104:488-96.
Svendsen MT, Feldman SR, Tiedemann SN, Sørensen ASS, Rivas CMR, Andersen KE. Psoriasis patient preferences for topical drugs: a systematic review. J Dermatolog Treat. 2021;32:478-83.
Thaçi D, de la Cueva P, Pink AE, Jalili A, Segaert S, Hjuler KF, et al. General practice recommendations for the topical treatment of psoriasis: a modified-Delphi approach. BJGP Open. 2020;4:bjgpopen20X101108.
Tan X, Feldman SR, Chang J, Balkrishnan R. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv. 2012;9:1263-71.
Plachouri K-M, Georgiou S. Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis. J Dermatolog Treat. 2019;30:668-73.
Mijaljica D, Spada F, Harrison IP. Topical moisturisers for the management of psoriasis vulgaris. In: Aghaei S, editor. Psoriasis - new research. London: IntechOpen; 2022. https://doi.org/10.5772/intechopen.101964
Pinter A, Green LJ, Selmer J, Praestegaard M, Gold LS, Augustin M, et al. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol. 2022;36:228-36.
Armstrong A, Pinter A, Selmer J, Praestegaard M, Reich A, Koo J. Pooled analysis demonstrating superior patient- reported psoriasis treatment outcomes for calcipotriene/betamethasone dipropionate cream versus suspension/gel. J Drugs Dermatol. 2022;21:242-8.
Tapinarof cream (Vtama) for psoriasis. Med Lett Drugs Ther. 2022;64:122-4.
Lebwohl MG, Stein Gold L, Strober B, Papp KA, Armstrong AW, Bagel J, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385:2219-29.
ZORYVE™ (roflumilast) cream, for topical use. Full prescribing information. 2022 [last accessed 2022 Aug 29]. Available from: https://www.arcutis.com/wp-content/uploads/USPI-roflumilast-cream-FDAapproved-V1-29Jul2022.pdf
Lebwohl MG, Kircik LH, Moore AY, Stein Gold L, Draelos ZD, Gooderham MJ, et al. Roflumilast cream, a once-daily, potent phosphodiesterase-4 inhibitor, in chronic plaque psoriasis patients: efficacy and safety from DERMIS-1 and DERMIS-2 phase 3 trials. J Cutan Med Surg. 2021;25(1 Suppl):78S-9S.